FDAnews
www.fdanews.com/articles/126921-poniard-announces-results-of-phase-3-picoplatin-trial

Poniard Announces Results of Phase 3 Picoplatin Trial

May 10, 2010
Poniard Pharmaceuticals, a biopharmaceutical company focused on innovative oncology therapies, Monday announced that data from the Phase 3 trial evaluating the efficacy and safety of picoplatin as a second-line treatment in small cell lung cancer has been accepted for an oral presentation during the American Society of Clinical Oncology  2010 Annual Meeting.
MarketWatch